Sight Sciences to Present at Two Upcoming Investor Conferences
Rhea-AI Summary
Sight Sciences (NASDAQ: SGHT) will present at two investor conferences in May 2026: the BofA Securities 2026 Health Care Conference in Las Vegas on May 13, 2026 at 3:15 pm PT / 6:15 pm ET, and the Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026 at 9:00 am PT / 12:00 pm ET.
According to Sight Sciences, interested parties can access live and archived webcasts via the company’s Investors website.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – SGHT
On the day this news was published, SGHT gained 3.02%, reflecting a moderate positive market reaction. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $6M to the company's valuation, bringing the market cap to $219.25M at that time.
Data tracked by StockTitan Argus on the day of publication.
MENLO PARK, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced plans to present at two upcoming conferences.
- BofA Securities 2026 Health Care Conference in Las Vegas, NV on Wednesday, May 13, 2026, at 3:15 pm PT / 6:15 pm ET.
- Stifel 2026 Virtual Ophthalmology Forum on Tuesday, May 26, 2026, at 9:00 am PT / 12:00 pm ET.
Interested parties may access a live and archived webcast of the presentation and fireside chat on the “Investors” section of the Company’s website at https://investors.sightsciences.com/.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System and OMNI® Edge Surgical System are implant-free, minimally invasive glaucoma surgery technologies indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical System is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.
Sight Sciences and TearCare are trademarks of Sight Sciences registered in the United States. OMNI, SION, SmartLids, and the Sight Sciences logo are trademarks of Sight Sciences registered in the United States, European Union and other territories.
© 2026 Sight Sciences. All rights reserved.
Media contact:
pr@sightsciences.com
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
investor.relations@sightsciences.com
